education
Download App
Indonesia
search
Masuk
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Country
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
search
UserName
Profession
Email
Account
Manage Account
Change Password
Sign Out
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Other Services
Education
Download App
Country
Indonesia
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
Account
Masuk
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Iklan
Iklan
MIMS home
Drugs
Info
Lexzepam 3
Lexzepam 3
bromazepam
Manufacturer:
Mersifarma TM
SELECT
Concise Prescribing Info
Bahasa Concise Prescribing Info
Concise Prescribing Info
Bahasa Concise Prescribing Info
Concise Prescribing Info
Contents
Bromazepam
Indications/Uses
Short-term treatment of psychoneurotic & emotional disorders related w/ anxiety in severe cases.
Dosage/Direction for Use
Adult
Usual dose: 1.5-3 mg 3 times daily.
Severe cases
6-12 mg daily in 2-3 divided doses. Max: 60 mg daily.
Elderly & debilitated patient
Max: 3 mg daily in divided doses.
Administration
May be taken with or without food.
Special Precautions
Discontinue treatment if anxiety, hallucination, insomnia & excitation occur.
Adverse Reactions
Drowsiness, sedation, muscle weakness, vertigo, headache, confusion, mental depression, tremor, visual disturbance, urinary retention, GI disturbances, salivation changes, amnesia.
View
ADR Reporting Link
Drug Interactions
Alcohol, neuroleptics, tranquilizer, antidepressant, hypnotic, analgesic, anesth drugs.
MIMS Class
Anxiolytics
ATC Classification
N05BA08 - bromazepam ; Belongs to the class of benzodiazepine derivatives anxiolytics. Used in the management of anxiety, agitation or tension.
Regulatory Classification
P
Presentation/Packing
Form
Lexzepam 3 tab 3 mg
Packing/Price
5 × 10's (Rp206,250/boks)
Iklan
Iklan
Iklan
Iklan
Iklan
Iklan
Iklan
Daftar Gratis untuk melanjutkan membaca
Lanjutkan dengan Google
Daftar dengan email
Sudah punya akun?
Masuk
Daftar Gratis untuk melanjutkan membaca
Lanjutkan dengan Google
Daftar dengan email
Sudah punya akun?
Masuk